Efficacy of Oral Tofacitinib in Combination of Narrow Band UVB in Treatment of Vitiligo (NB-UVB)

Lahore General Hospital

Status and phase: Active, not recruiting; Phase 1

Conditions: Vitiligo

Treatments: Drug: Tofacitinib; Drug: Azathioprine

Study type: Interventional

Funder types: Other

Identifiers

NCT07044141

Dermatology LGH

Details and patient eligibility

About

20 patients will be enrolled. All were given narrowband UVB . 10 wil be give oral azathriopfine . 10 will be given tofacitinib

Full description

Total 20 patients will be enrolled. All were given narrowband UVB . 10 wil be give oral azathriopfine 50mg twice daily. 10 will be given tofacitinib 5mg twice daily. For 6 months

Enrollment: 20 estimated patients

Sex: All

Ages: 18 to 60 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• patient of vitiligo with any VASI both genders 18 to 60yrs

Exclusion criteria

• pregnancy/lactation Hyerlipidrmia Patient on immunemodulator Histry pf tuberculosis Immunocompromised patients

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

20 participants in 2 patient groups

Group A

Active Comparator group

Description:

Azathioprine is an immunomodulator used in treatment of vitiligo

Treatment:

Drug: Azathioprine

Group B

Active Comparator group

Description:

Tofacitinib It is a Janu kinase pathway inhibitor

Treatment:

Drug: Tofacitinib